-
Mashup Score: 2
Samer A. Al’Hadidi, MD, discusses the follow-up data for ciltacabtagene autoleucel in patients with multiple myeloma.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 1
A panel of experts on multiple myeloma discuss the role of CAR T-cell therapy in the evolving treatment landscape, highlighting clinical trial data, recent approvals, and clinical practices.
Source: www.cancernetwork.comCategories: General Medicine News, Oncologists1Tweet-
A panel of experts on multiple myeloma discuss the role of CAR T-cell therapy in the evolving treatment landscape, highlighting clinical trial data, recent approvals, and clinical practices. #mmsm | @szusmani @RahulBanerjeeMD https://t.co/LVjNoCqtlS https://t.co/j3td9T3bQu
-
-
Mashup Score: 0Treatment Sequencing Strategies in R/R Multiple Myeloma - 2 day(s) ago
A panel of experts on multiple myeloma review patient cases and discuss the treatment of patients with relapsed/refractory disease, highlighting sequencing strategies and clinical trials that are informing treatment decisions.
Source: www.cancernetwork.comCategories: General Medicine News, Oncologists1Tweet-
Multiple myeloma experts discuss the treatment of patients with relapsed/refractory disease, highlighting sequencing strategies and clinical trials that are informing treatment decisions. #mmsm | @Rfonsi1 @SurbhiSidanaMD @bhemato @Dr_AdrianaRossi https://t.co/J252HQCQQi https://t.co/VhfJWZPVly
-
-
Mashup Score: 5
Panelists discuss how health care providers engage in vital conversations with patients about CAR T therapy, focusing on comprehensive education, emotional support, and clear communication about the treatment journey ahead.
Source: www.cancernetwork.comCategories: General Medicine News, Oncologists1Tweet-
Panelists discuss how health care providers engage in vital conversations with patients about CAR T therapy, focusing on comprehensive education, emotional support, and clear communication about the treatment journey ahead. #mmsm | @bhemato https://t.co/E0Pdi9HVyY
-
-
Mashup Score: 16Impatient for Outpatient: Operationalizing Bispecific Antibodies for Multiple Myeloma in the Ambulatory Setting | JCO Oncology Practice - 4 day(s) ago
In the article that accompanies this editorial, Sandahl et al 1 describe the successful implementation of an outpatient-based workflow for teclistamab administration. Teclistamab, a bispecific antibody (bsAb) targeting both CD3 on T cells and B-cell maturation antigen (BCMA) on plasma cells, was the first bsAb to receive US Food and Drug Administration (FDA) approval in relapsed/refractory (R/R) multiple myeloma (MM) on the basis of the results of the MajesTEC-1 trial. In updated results from this trial,
Source: ascopubs.orgCategories: General Medicine News, Partners & KOLsTweet-
And thanks @JCOOP_ASCO for invitation for Dan Oliveri (@UWMedicine resident) & me to comment on outpatient bsAb SUD in any cancer (inc #MMsm). Many strategies to operationalize OP bsAbs: PPx toci, "pocket" dex prn CRS, RPM 📲, and more. Can use ≥1! https://t.co/lZ8YE1Pw70 https://t.co/mODNw7sXPm https://t.co/gncfK7Ros0
-
-
Mashup Score: 57
PURPOSETeclistamab is initiated with a step-up dosing (SUD) schedule to mitigate the risk of cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS). Early teclistamab users commonly received SUD in a hospital …
Source: ascopubs.orgCategories: General Medicine News, Partners & KOLsTweet-
Great to see in @JCOOP_ASCO - Mayo experience with outpt teclistamab step-up dosing in #MMsm. This is where the field is headed, and impressive to see how quickly @MayoMyeloma campuses moved there - and how much this ⬇️ time toxicity for patients! https://t.co/iSquYNCsqN https://t.co/rTjmzXN7Uj
-
-
Mashup Score: 13Fellow's Perspective: Impact of Quadruplet and MRD in Newly Diagnosed Multiple Myeloma - 5 day(s) ago
In a discussion with Peers & Perspectives in Oncology, fellowship program director Marc J. Braunstein, MD, PhD, FACP, and hematology/oncology fellow Olivia Main, MD, talk about how recent trials shape their approach for a patient with transplant-eligible multiple myeloma.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet-
Marc J. Braunstein, MD, PhD, FACP, (@docbraunstein) and hematology/oncology fellow Olivia Main, MD, talk about how recent trials shape their approach for a patient with transplant-eligible multiple myeloma. #mmsm | @Perlmutter_CC @NYULISOM_HemOnc https://t.co/XcZIluizO1 https://t.co/vsZ1RPfSoC
-
-
Mashup Score: 5Optimizing Transition of Care in Multiple Myeloma: Bridging the Gap Between Academic and Community Settings - 5 day(s) ago
A panel of experts on multiple myeloma share clinical practices and discuss the transition of care between academic and community oncology settings.
Source: www.cancernetwork.comCategories: General Medicine News, Oncologists1Tweet-
A panel of experts on multiple myeloma share clinical practices and discuss the transition of care between academic and community oncology settings. #mmsm | @DoctorAKrishnan @szusmani https://t.co/bepeqTFWoz https://t.co/g5zNNmZwdI
-
-
Mashup Score: 2
During a Case-Based Roundtable® event, Omar Nadeem, MD, and participants discussed managing toxicities of talquetamab in the second article of a 2-part series.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet-
Omar Nadeem, MD, (@OmarNadeemMD) and participants discussed managing toxicities of talquetamab. #MMSM | @DanaFarber @harvardmed https://t.co/aWwNZ5XMAt
-
-
Mashup Score: 2
Following the 2024 ASCO Annual Meeting, a panel of experts on multiple myeloma review recent updates and discuss evolving treatment practices.
Source: www.cancernetwork.comCategories: General Medicine News, Oncologists1Tweet-
Following the 2024 ASCO Annual Meeting, a panel of experts on multiple myeloma review recent updates and discuss evolving treatment practices. #mmsm | @Rfonsi1 @HadidiSamer https://t.co/7S38KEoYYI https://t.co/L84VYVvCBD
-
WATCH: Samer A. Al’Hadidi, MD, (@HadidiSamer) discusses the follow-up data for ciltacabtagene autoleucel in patients with multiple myeloma. #mmsm @UAMSMyeloma https://t.co/d12pNOtWHo